Back to results
US 2024/0016925 A1Published application
Novel vaccine adjuvant
AssigneeSl Vaxigen, Inc.
InventorsYong Bok SEO, Youngwoo CHOI, Sang Hee SIM
Life of this patent
Estimating the term…
Abstract
There is provided a novel vaccine adjuvant, and more specifically, a vaccine adjuvant for stimulating a T lymphocyte-specific immune response, which includes an IL-12 protein and an IL-21 protein as active ingredients, or includes the polynucleotide encoding an IL-12 protein and the polynucleotide encoding an IL-21 protein as active ingredients.
Claims14
-16. (canceled)
A method for stimulating a T lymphocyte-specific immune response by a vaccine composition in a subject comprising administering an adjuvant composition comprising i) IL-12 protein and IL-21 protein;
- or ii) a polynucleotide encoding a p35 chain of IL-12 protein (IL-12p35), a polynucleotide encoding a p40 chain of IL-12 protein (IL-12p40) and a polynucleotide encoding an IL-21 protein along with the vaccine composition to the subject,
- wherein the adjuvant composition induces a lower antibody response compared to when the vaccine composition is treated alone.
Dependencies are inferred from the claim text.